Skip to main content Accessibility help
×
Home

Hepatitis B virus in drug users in France: prevalence and vaccination history, ANRS-Coquelicot Survey 2011–2013

  • C. BROUARD (a1), J. PILLONEL (a1), P. SOGNI (a2) (a3) (a4), A. CHOLLET (a5), J. V. LAZARUS (a6) (a7), X. PASCAL (a5), F. BARIN (a8), M. JAUFFRET-ROUSTIDE (a1) (a5) and the ANRS Coquelicot Survey Group...

Summary

People who use drugs (PWUD) are a key population for hepatitis B virus (HBV) vaccination and screening. We aimed to estimate the seroprevalence of HBs antigen (HBsAg) and self-reported HBV vaccination history in French PWUD attending harm reduction centres using data from the ANRS-Coquelicot multicentre survey conducted in 2011–2013 in 1718 PWUD. Self-fingerprick blood samples were collected on dried blood spots to detect the presence of HBsAg. HBsAg seroprevalence was estimated at 1·4% [95% confidence interval (CI) 0·8–2·5]. It varied between PWUD born in high (7·6%, 95% CI 2·7–19·1), moderate (2·2%, 95% CI 0·8–5·7) and low (0·7%, 95% CI 0·3–1·5) endemic zones. Factors independently associated with HBsAg carriage were being born in a moderate or high endemic zone or reporting precarious housing. Self-reported HBV vaccination history varied from 47·4% in high endemic zones, to 59·3% and 62·6% for moderate and low endemic zones, respectively. Our results suggest that drug use plays a small and substantial role, respectively, in HBsAg carriage in PWUD born in high/moderate and low endemic zones.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Hepatitis B virus in drug users in France: prevalence and vaccination history, ANRS-Coquelicot Survey 2011–2013
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Hepatitis B virus in drug users in France: prevalence and vaccination history, ANRS-Coquelicot Survey 2011–2013
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Hepatitis B virus in drug users in France: prevalence and vaccination history, ANRS-Coquelicot Survey 2011–2013
      Available formats
      ×

Copyright

Corresponding author

*Author for correspondence: Mrs M. Jauffret-Roustide, Cermes3, 45 rue des Saints-Pères, 75006 Paris, France, (Email: marie.jauffretroustide@santepubliquefrance.fr; marie.jauffret-roustide@inserm.fr)

Footnotes

Hide All
† Members of the ANRS Coquelicot Survey Group are given in the Appendix.

Footnotes

References

Hide All
1. Schweitzer, A, et al. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet 2015; 386: 15461555.
2. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015; 385: 117171.
3. Locarnini, S, et al. Strategies to control hepatitis B: Public policy, epidemiology, vaccine and drugs. Journal of Hepatology 2015; 62: S7686.
4. Meffre, C, et al. Prevalence of hepatitis B and hepatitis C virus infections in France in 2004: social factors are important predictors after adjusting for known risk factors. Journal of Medical Virology 2010; 82: 546555.
5. World Health Organization. Hepatitis B. Fact sheet no. 204 (http://www.who.int/mediacentre/factsheets/fs204/en/). Accessed 19 May 2016.
6. Denis, F, Levy-Bruhl, D. Mass vaccination against hepatitis B: the French example. Current Topics of Microbiology and Immunology 2006; 304: 115129.
7. World Health Organization. 63rd World Health Assembly: Resolution A63/15: Viral Hepatitis (http://apps.who.int/gb/ebwha/pdf_files/WHA63/A63_15-en.pdf). Accessed 23 May 2016.
8. Mathers, BM, et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet 2008; 372: 17331745.
9. Weill-Barillet, L, et al. Hepatitis C virus and HIV seroprevalences, sociodemographic characteristics, behaviors and access to syringes among drug users, a comparison of geographical areas in France, ANRS-Coquelicot 2011 survey. Revue d'Epidemiologie et de SantéPublique 2016; 64: 301312.
10. Jauffret-Roustide, M, et al. A national cross-sectional study among drug-users in France: epidemiology of HCV and highlight on practical and statistical aspects of the design. BMC Infectious Diseases 2009; 9: 113.
11. Mohamed, S, et al. Dried blood spot sampling for hepatitis B virus serology and molecular testing. PLoS ONE 2013; 8: e61077.
12. Njai, HF, et al. Validation of rapid point-of-care (POC) tests for detection of hepatitis B surface antigen in field and laboratory settings in the Gambia, Western Africa. Journal of Clinical Microbiology 2015; 53: 11561163.
13. Chan, HL, et al. Hepatitis B surface antigen quantification: why and how to use it in 2011 – a core group report. Journal of Hepatology 2011; 55: 11211131.
14. European Monitoring Center for Drugs and Drug Addiction. HBsAg prevalence. European Data 2015 (http://www.emcdda.europa.eu/data/stats2015). Accessed 4 June 2016.
15. Lugoboni, F, et al. Let It ‘B’? The role of hepatitis B universal vaccination among italian problematic drug users. International Journal of Environmental Research and Public Health 2015; 12: 39793992.
16. Public Health England. Data tables of the Unlinked Anonymous Monitoring Survey of HIV and Hepatitis in People Who Inject Drugs 2014 (https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/326897/UAM_Survey_of_PWID_data_tables_2014.pdf). Accessed 28 May 2016.
17. Bialek, SR, et al. Risk factors for hepatitis B in an outbreak of hepatitis B and D among injection drug users. Journal of Urban Health 2005; 82: 468478.
18. Des Jarlais, DC, Braine, N, Friedmann, P. Unstable housing as a factor for increased injection risk behavior at US syringe exchange programs. AIDS and Behavior 2007; 11: 7884.
19. Brouard, C, et al. Hepatitis B knowledge, perceptions and practices in the French general population: the room for improvement. BMC Public Health 2013; 13: 576.
20. Di, Nino F, et al. Evolution of hepatitis B vaccination coverage among psychoactive substances users followed by the Network of Medical Microstructures in Alsace (France), 2009–2012. Bulletin Epidemiologique Hebdomadaire 2014; 11: 192200.
21. Day, CA, et al. Hepatitis B virus among injecting drug users in Sydney, Australia: prevalence, vaccination and knowledge of status. Drug and Alcohol Dependence 2010; 108: 134137.
22. Kamath, GR, Shah, DP, Hwang, LY. Immune response to hepatitis B vaccination in drug using populations: a systematic review and meta-regression analysis. Vaccine 2014; 32: 22652274.
23. Topp, L, et al. Poor criterion validity of self-reported hepatitis B infection and vaccination status among injecting drug users: a review. Drug and Alcohol Revue 2009; 28: 669675.
24. Quaglio, G, et al. Hepatitis vaccination among drug users. Vaccine 2006; 24: 27022709.
25. Judd, A, et al. Twenty years of selective hepatitis B vaccination: is hepatitis B declining among injecting drug users in England and Wales? Journal of Viral Hepatitis 2007; 14: 584591.
26. Mossner, BK, et al. Decline in hepatitis B infection observed after 11 years of regional vaccination among Danish drug users. Journal of Medical Virology 2010; 82: 16351639.
27. Guthmann, JP, et al. Hepatitis B vaccination coverage among children in France in 2014: substantial progress in infants, stagnation in adolescents. Bulletin Epidemiologique Hebdomadaire 2015; 26–27: 499504.
28. Bowman, S, et al. Factors associated with hepatitis B vaccine series completion in a randomized trial for injection drug users reached through syringe exchange programs in three US cities. BMC Public Health 2014; 14: 820.
29. Shah, DP, et al. Long-term effectiveness of accelerated hepatitis B vaccination schedule in drug users. American Journal of Public Health 2015; 105: e3643.
30. Weaver, T, et al. Use of contingency management incentives to improve completion of hepatitis B vaccination in people undergoing treatment for heroin dependence: a cluster randomised trial. Lancet 2014; 384: 153163.
31. Topp, L, et al. A randomised controlled trial of financial incentives to increase hepatitis B vaccination completion among people who inject drugs in Australia. Preventive Medicine 2013; 57: 297303.

Keywords

Related content

Powered by UNSILO

Hepatitis B virus in drug users in France: prevalence and vaccination history, ANRS-Coquelicot Survey 2011–2013

  • C. BROUARD (a1), J. PILLONEL (a1), P. SOGNI (a2) (a3) (a4), A. CHOLLET (a5), J. V. LAZARUS (a6) (a7), X. PASCAL (a5), F. BARIN (a8), M. JAUFFRET-ROUSTIDE (a1) (a5) and the ANRS Coquelicot Survey Group...

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed.